Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 7.3% – Here’s What Happened

Posted by George Bondi on Aug 2nd, 2026

Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report)’s stock price traded down 7.3% on Friday . The company traded as low as $16.19 and last traded at $16.2360. 229,340 shares changed hands during mid-day trading, a decline of 74% from the average daily volume of 884,287 shares. The stock had previously closed at $17.52.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Wall Street Zen cut Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Cullinan Therapeutics in a research note on Wednesday, July 8th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Cullinan Therapeutics in a report on Monday, June 8th. BTIG Research upped their target price on Cullinan Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Wedbush reiterated an “outperform” rating and set a $37.00 target price on shares of Cullinan Therapeutics in a research note on Thursday, June 11th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $32.14.

View Our Latest Stock Report on CGEM

Cullinan Therapeutics Stock Performance

The business’s 50 day moving average price is $16.38 and its 200-day moving average price is $14.57. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -4.91 and a beta of -0.01.

Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.09. On average, analysts forecast that Cullinan Therapeutics, Inc. will post -3.06 earnings per share for the current fiscal year.

Insider Activity at Cullinan Therapeutics

In other news, insider Jennifer Michaelson sold 8,000 shares of Cullinan Therapeutics stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $17.82, for a total value of $142,560.00. Following the completion of the transaction, the insider owned 162,844 shares in the company, valued at approximately $2,901,880.08. This trade represents a 4.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Cullinan Therapeutics

Several large investors have recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Cullinan Therapeutics by 1.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 48,051 shares of the company’s stock worth $497,000 after purchasing an additional 888 shares during the period. Caitong International Asset Management Co. Ltd raised its holdings in shares of Cullinan Therapeutics by 62.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,696 shares of the company’s stock worth $28,000 after purchasing an additional 1,036 shares during the period. AlphaCentric Advisors LLC lifted its position in shares of Cullinan Therapeutics by 5.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 20,135 shares of the company’s stock worth $286,000 after buying an additional 1,094 shares during the last quarter. Kennedy Capital Management LLC lifted its position in shares of Cullinan Therapeutics by 2.7% in the 4th quarter. Kennedy Capital Management LLC now owns 47,266 shares of the company’s stock worth $489,000 after buying an additional 1,255 shares during the last quarter. Finally, CWM LLC boosted its holdings in shares of Cullinan Therapeutics by 51.5% in the 4th quarter. CWM LLC now owns 3,876 shares of the company’s stock valued at $40,000 after buying an additional 1,318 shares during the period. 86.31% of the stock is currently owned by institutional investors.

Cullinan Therapeutics Company Profile

(Get Free Report)

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.